Chronotherapy for gastrointestinal cancers

Current Opinion in Oncology

Volumn 8, Issue 4, 1996, Pages 334-341

  Lévi, Francis ^a  

^a HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; MITOMYCIN C; NAVELBINE; OXALIPLATIN;

ANTINEOPLASTIC ACTIVITY; CHRONOTROPISM; CIRCADIAN RHYTHM; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DRUG TOLERABILITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER CANCER; MOUSE; MUCOSA INFLAMMATION; NEUROPATHY; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STOMACH CANCER;

EID: 0029779736     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199607000-00012     Document Type: Review

References (61)

1. Lévi F, Perpoint B, Garufi C, Focan C, Chollet P, Deprés-Brummer P, Zidani R, Brienza S, Itzhaki M, Iacobelli S, Kunstlinger F, Gastiaburu J, Misset JL: Oxaliplatin activity against metastatic colorectal cancer: a phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate, Eur J Cancer 1993, 29:1280-1284.
2. Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu J-J, Brienza S, Itzhaki M, Metzger G, N'Daw D, Vignoud J, Abad A, François E, Gamelin E, Marty M, Sastre J, Seitz J-F, Ychou M: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996, 7:95-98.
3. Abigerges D, Chabot GG, Armand JP, Hérart P, Gouyette A, Gandia D: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995, 13:210-221. A large phase I and pharmacokinetic-pharmacodynamic study that documents severe diarrhea as the main dose-limiting toxicity of irinotecan, with the possibility to overcome it with high-dose loperamide, and to reach myelotoxicity as an alternative dose-limiting toxicity. Correlations between toxicity and irinotecan and SN38 (main metabolite) area under the concentration × time curve were found. There was an apparent dose-efficacy relationship, which suggests the more, the better.
4. Mathé G, Kidani Y, Segiguchi M, Eriguchi M, Fredj G, Peytavin G, Misset JL, Brienza S, de Vassals F, Chenu E, Bourut C: Oxalato platinum or L-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother 1989, 43:237-250.
5. Caussanel JP, Lévi F, Brienza S, Misset JL, Itzhaki M, Adam R, Milano G, Hecquet B, Mathé G: Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 1990, 82:1046-1050.
6. Extra JM, Espie M, Calvo F, et al.: Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990, 25:299-303.
7. Conroy T, Etienne PL, Adenis A, Theo Wagener DJ, Paillot B, François E, Bedenne L, Jacob JH, Seitz JF, Bleiberg H, van Pottelsberghe C, van Glabbeke M, Delgado FM, Merle S, Wils J, for The European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group: Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. J Clin Oncol 1996, 14:164-170.
8. Lévi F, Brienza S, Metzger G, Deprés-Brummer P, Bertheault-Cvitkovic F, Zidani R, Adam R, Misset JL: Implications of Chronobiology for 5-Fluorouracil (5-FU) Efficacy. In Novel Approaches to Selective Treatments of Human Solid Tumors; Laboratory and Clinical Correlation. Edited by Rustum YM. Plenum Press: New York; 1993:169-186.
9. Boughattas N, Lévi F, Fournier C, Lemaigre G, Roulon A, Hecquet B, Mathé G, Reinberg A: Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane (trans-1) oxalatoplatinum (II) in mice. Cancer Res 1989, 49:3362-3368.
10. Tampellini M, Filipski E, Lévi F: Circadian variation of vinorelbine toxicity in mice. Chronobiol Intern 1995, 12:195-198.
11. Peters GJ, van DiJk J, Nadal JC, van Groeningen CS, Lankelma J, Pinedo HM: Diurnal variation in the therapeutic efficacy of 5-fluorouracil against murine colon cancer. In Vivo 1987, 1:113-118.
12. Sothern R, Lévi F, Haus E, Halberg F, Hrushesky WJM: Control of a murine plasmacytoma with doxorubicin-cisplatin: dependence on circadian stage of treatment J Natl Cancer Inst 1989, 81:135-145.
13. Lévi F. Chronopharmacology of Anticancer Agents. In Handbook of Experimental Pharmacology: Physiology and Pharmacology of Biological Rhythms. Cancer Chemotherapy. Edited by Redfern PH, Lemmer B. Springer-Verlag: Berlin; 1996, in press.
14. Lévi F, Giacchetti S, Adam R, Zidani R, Metzger G, Misset JL: Chronomodulation of chemotherapy against metastatic colorectal cancer. Eur J Cancer 1995, 31A:1264-1271.
15. Harris B, Song R, Soong S, Diasio RB: Circadian variation of 5-fluorouracil catabolism in isolated perfused rat Cancer Res 1989, 49:6610-6614.
16. Zhang R, Lu Z, Liu T, Soong SJ, Diasio RB: Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy. Cancer Res 1993, 53:2816-2822.
17. Codacci-Pisanelli G, van der Wilt CL, Pinedo HM, Franchi F, Noordhuis P, Braakhuis BJM, van Laar JAM, Peters GJ: Antitumor activity, toxicity and inhibition of thymidylate synthese of prolonged administration of 5-fluorouracil in mice. Eur J Cancer 1995, 31A:1517-1525.
18. Boughattas NA, Hecquet H, Fournier C, Bruguerolle B, Trabelsi H, Bouzouita K, Omrane B, Lévi F: Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time. Biopharm Drug Dispos 1994, 15:1-13.
19. Smaaland R, Laerum OD, Sothern RB, Sletvold O, Bjerknes R, Lote K: Colony-forming unit-granulocyte-macrophage and DNA synthesis of human bone marrow are circadian stage-dependent and show covariation. Blood 1992, 79:2281-2287.
20. Buchi KN, Moore JG, Hrushesky WJM, et al.: Circadian rhythm of cellular proliferation in the human rectal mucosa. Gastroenterol 1991, 101:410-415.
21. Warnakulasuriya KAAS, Macdonald DG: Diurnal variation in labelling index in human buccal epithelium. Arch Oral Biol 1993, 12:1107-1111.
22. Brown WR: A review and mathematical analysis of circadian rhythms in cell proliferation in mouse, rat and human epidermis. J Invest Dermatol 1991, 97:273-280.
23. Harris B, Song R, Soong S, Diasio RB: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels: evidence for circadian variation of plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990, 50:197-201.
24. Lévi F, Blazsek I, Ferlé-Vidovic A: Circadian and seasonal rhythms in murine bone marrow colony-forming cells affect tolerance for the anticancer agent 4'-0-tetrahydropyranyladriamycin (THP). Exp Hematol 1988, 16:696-701.
25. Petit E, Milano G, Lévi F, Thyss A, Bailleul F, Schneider M: Circadian varying plasma concentration of S-FU during 5-day continuous venous infusion at constant rate in cancer patients. Cancer Res 1988, 48:1676-1679.
26. Metzger G, Massari C, Etienne MC, Commisso M, Brienza S, Touitou Y, Milano G, Bastian G, Misset JL, Lévi F: Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in cancer patients. Clin Pharmacol Ther 1994, 56:190-201.
27. Hryniuk WM, Figueredo A, Goodyear M: Applications of dose-intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 1987, 14:3-11.
28. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992, 10:896-903.
29. Advanced Colorectal Cancer Meta-Analysis Project: Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994, 12:960-969.
30. Zalcberg JR, Siderov J, Simes J, for the Australasian Gastrointestinal Trials Group: The role of 5-fluorouracil dose in the adjuvant therapy of colorectal cancer. Ann Oncol 1996, 7:41-46.
31. Roemeling R, Hrushesky WM: Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer. J Clin Oncol 1989, 7:1710-1719.
32. Lévi F, Soussan A, Adam R, Caussanel JP, Metzger G, Jasmin C, Bismuth H, Smolensky M, Misset JL: A phase I-II trial of five-day continuous intravenous infusion of 5-fluorouracil delivered at circadian rhythm modulated rate in patients with metastatic colorectal cancer. J Infus Chemother 1995, 5:153-158.
33. Garufi C, Giunta S, Aschelter A, Nistico C, Narduzzi C, Silecchia GF, Terzoli E: A phase I time modulated infusion of high doses of fluorouracil (FU) and I-folinic acid (L-FA) in advanced colorectal cancer: toxicity and response rate [abstract]. Proceeding 6th International Conference Chronopharmacology Chronotherapy: Amelia Island, FI; 1994:VIIIb-11.
34. Chollet PH, Curé H, Garufi C, Focan C, Pezet D, Giunta S, Terzoli E, Ravoux MA, Martineau N, Chipponi J, Lévi F: Phase II trial with chronomodulated 5-fluorouracil (5-FU) and folinic acid (FA) in metastatic colorectal cancer [abstract]. Proc 6th Intern Conf Chronopharm Chronother. Amelia Island, FL; 1994:VIIIb-4.
35. Adler S, Lang S, Langenmayer I, Eibl-Eisbesfeldt B, Rump W, Emmerich B, Hallek M: Chronotherapy with 5-fluoruracil and folinic acid in advanced colorectal carcinoma: results of a chronopharmacologic phase I trial. Cancer 1994, 73:2905-2912.
36. Bjarnason G, Kerr J, Doyle N, et al.: Phase I study of 5-fluorouracil and leucovorin by a 14-day circadian infusion in patients with metastatic adenocarcinoma. Cancer Chemother Pharmacol 1993, 33:221-228.
37. Lévi F, Misset JL, Brienza S Adam R, Metzger G, Itzhaki M, Caussanel JP, Kunstlinger F, Lecouturier S, Descorps-Declére A, Jasmin C, Bismuth H, Reinberg A: A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump: high antitumor effectiveness against metastatic colorectal cancer. Cancer 1992, 69:893-900.
38. Lévi F, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, Chollet P, Garufi C, Itzhaki M, Dogliotti L, Iacobelli S, Adam R, Kunstlinger F, Gastiaburu J, Bismuth H, Jasmin C, Misset JL: Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with colorectal cancer metastases: a randomized multiinstitutional trial. J Natl Cancer Inst 1994, 86:1608-1617.
39. Lévi F, Zidani R, Vannetzel JM, Faggiuolo R, Garufi C, Chollet P, Focan C, Perpoint B, Iacobelli S, Le Rol A, Deprés-Brummer P, Itzhaki M, Misset JL: Chronomodulated versus flat infusion of 5-fluorouracil (5-FU), folinic acid (FA) and oxaliplatin (L-OHP) against metastatic colorectal cancer (MCC) in 2 consecutive european randomized multicenter trials (T) [abstract]. Proceedings of 31st Annual Meeting of the American Society of Clinical Oncology. Los Angeles, CA: 1995, volume 14.
40. Bertheault-Cvitkovic F, Jami A, Ithzaki M, Deprés-Brummer P, Brienza S, Adam R, Bismuth H, Misset JM, Lévi F: Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with metastatic colorectal cancer. J Clin Oncol 1996, in press.
41. Lévi F, Zidani R, Faggiuolo R, Focan C, Pezet D, Giunta S, Terzoli E, Ravoux MA, Martineau N, Chipponi J, Lévi F: A European multicenter phase II trial of intensified 4-day every-two-weeks chronotherapy with oxaliplatin (L-OHP), 5-fluorouracil (S-FU) and folinic acid (FA) in 102 patients (pts) with metastatic colorectal cancer [abstract #215]: Proc. 19th ESMO Congress. Lisbon, Portugal. Ann Oncol 1994, 5(suppl 8):.
42. Giacchetti S, Gruia G, Itzhaki M, Adam R, Brienza S, Deprés-Brummer P, Bertheault-Cvitkovic F, Bismuth H, Cvitkovic E, Misset JL, Lévi F: Surgery after chronomodulated chemotherapy with S-fluorouracil (S-FU), folinic acid (FA) and oxaliplatin (L-OHP) (chrono) allows long term survival of patients (pts) with unresectable colorectal liver metastases [abstract]. Proceedings 31st Annual Meeting of the American Society of Clinical Oncology. Los Angeles, CA: 14:204.
43. Hill M, Norman A, Cunningham D, Findlay M, Nicolson V, Hill A, Iveson A, Evans C, Joffe J, Nicolson M, Hickish T: Royal Mardsen phase III trial of fluorouracil with of without Interferon alpha-2b in advanced colorectal cancer. J Clin Oncol 1995, 13:1297-1302.
44. Köhne CH, Wilke H, Hecker H , Schöffski P, Käufer C, Rauschecker H, Andreesen R, Ohl U, Lange HJ, Klaassen U, Westerhausen M, Hiddemann W, Hennemann B, Schott G, Bade J, Strohmeyer G, Harstrick A, Schubert U, Bokemeyer C, Schmoll HJ: Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. Ann Oncol 1995. 6:461-466.
45. Jones DV, Winn RJ, Brown BW, Levy LB, Pugh RP, Wade JI III, Gross HM, Pendergrass KB, Levin B, Abbruzzese JL: Randomized phase III study of 5-fluoruracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-fomustine for patients with advanced colorectal cancer. Cancer 1995, 76:1709-1714.
46. Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalik A, Macdonald JS: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995, 13:1303-1311. Seven nonchronobiologic 5-FU schemes produced similar results with regard to response rate or survival in a total of 620 patients. Fewest toxic effects were however encountered in the infusional arms (protracted or 24-hour).
47. Brennan MF, Kinsella T, Friedman M: Cancer of the Pancreas. In Cancer. Principles and Practice on Oncology. Edited by de Vita VT, Hellman S, Rosenberg SA. J.B. Lippincott; Philadelphia; 1993:800-835.
48. Cullinam S, Moertlel C, Wicand H, et al.: A Phase III trial on the therapy of advanced pancreatic carcinoma. Cancer 1990, 65:2207-2212.
49. Palmer KR, Kerr M, Knowles G, et al.: Chemotherapy prolongs survival in inoperable pancreatic cancer. Br J Surg 1994, 81:882-885.
50. Bertheault-Cvitkovic F, Lévi F, Soussan S, Brienza S, Adam R, Itzhaki M, Misset JL, Bismuth H: Circadian-rhythm modulated chemotherapy with high-dose 5-fluorouracil: a pilot study in patients with pancreatic adenocarcinoma. Eur J Cancer 1993, 29A:1851-1854.
51. Rougier P, Zarba JJ, Basile M, et al. Phase II study of cisplatin and 120 hours continuous infusion of 5-fluorouracil in patients with advanced pancreatic cancer. Ann Oncol 1993, 4:333-336.
52. Whittington R, Neuberg D, Tester WJ, Benson AB III, Haller DG: Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a phase I Eastern Cooperative Oncology Group trial. J Clin Oncol 1995, 13:227-232.
53. Nicholson M, Webb A, Cunningham D, Norman A, O'brien M, Hill A, Hickish T: Cisplatin and protracted venous infusion 5-fluorouracil (CF): good symptom relief with low toxicity in advanced pancreatic carcinoma. Ann Oncol 1995, 6:801-884.
54. Herskovic A, Martz K, Al-Sarraf M, et al.: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the oesophagus. N Engl J Med 1992, 326:1593-1598.
55. Focan C, Denis B, Dallemagne B, Fontaine F, Delforge M, Dohogne A, Weerts J: Ambulatory chronotherapy with 5-fluorouracil, folinic acid and carboplatin with combined radiotherapy for advanced esophagus cancer: a preliminary report [abstract]. Biol Rhythm Res 1995, 26.389.
56. Vincent M, Lévi F, Girodet B, Laennec E, Poirie P, Guibert B, Ardiet JM, Renaudier P, van-Straaten L: Circadian chemotherapy against stage IIIB-4 non-small-cell lung cancer (NSCLC) with 5-fluorouracil (5-FU, folinic acid (FOL) and cisplatinum (CDDP) via a multichannel programmable pump [abstract]. Proceeding 6th International Conference Chronopharmacology Chronotherapy. Biological Rhythms and Medications, Amelia Island, FL; 1994:VIIIb-7.
57. Stangl R, Altendorl-Hofmann A, Charnley RM, Scheele J: Factors influencing the natural history of colorectal liver metastases. Lancet 1994, 343:1405-1410.
58. Peters GJ, van der Wilt CL, van Groeningen CJ: Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase. Eur J Cancer 1994, 30A:1408-1411.
59. Etienne MC, Chéradame S, Fischel JL, Formento P, Dassonville O, Renée N, Schneider M, Thyss A, Demard F, Milano G: Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995, 13:1663-1670
60. Touitou Y, Lévi F, Bogdan A, Benavides M, Bailleul F, Misset JL: Circadian desynchronization of blood variables in patients with metastatic breast cancer: role of prognostic factors. J Cancer Res Clin Oncol 1995, 121:181-188.
61. Benavides M: Cancer avancé de l'ovaire: approche chronobiologique comme nouvelle stratégie du traitement et de la surveillance clinique et biologique. Thèse de Doctorat en Cancérologie. Université Paris XI; 1991.